Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Expected to Post Quarterly Sales of $101.44 Million

Wall Street brokerages forecast that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Rating) will announce sales of $101.44 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Ironwood Pharmaceuticals’ earnings. The highest sales estimate is $105.50 million and the lowest is $96.01 million. Ironwood Pharmaceuticals reported sales of $104.03 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 2.5%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Ironwood Pharmaceuticals will report full-year sales of $426.60 million for the current financial year, with estimates ranging from $421.70 million to $429.70 million. For the next year, analysts anticipate that the firm will post sales of $460.13 million, with estimates ranging from $458.30 million to $461.95 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.10). The company had revenue of $97.53 million for the quarter, compared to analyst estimates of $96.62 million. Ironwood Pharmaceuticals had a return on equity of 33.93% and a net margin of 124.83%. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 EPS.

A number of research firms recently commented on IRWD. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 26th. Piper Sandler began coverage on shares of Ironwood Pharmaceuticals in a research report on Friday, April 22nd. They set an “overweight” rating and a $16.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average price target of $14.75.

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 3,031 shares of the firm’s stock in a transaction dated Thursday, March 24th. The shares were sold at an average price of $12.75, for a total value of $38,645.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 12.60% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd bought a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at about $43,000. Aaron Wealth Advisors LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at approximately $290,000. Moors & Cabot Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $562,000. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at approximately $63,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at approximately $78,000.

NASDAQ:IRWD opened at $11.46 on Friday. Ironwood Pharmaceuticals has a 52 week low of $10.13 and a 52 week high of $14.27. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of 3.59 and a beta of 1.17. The firm’s 50-day simple moving average is $12.16 and its 200 day simple moving average is $11.69. The company has a debt-to-equity ratio of 0.56, a quick ratio of 4.61 and a current ratio of 4.61.

Ironwood Pharmaceuticals Company Profile (Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

Featured Stories

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.